Effects of hypersecretion of growth hormone and prolactin on plasma levels of glucagon and insulin in GH3-cell-tumor-bearing rats, and the influence of bromocriptine treatment.
Plasma levels of prolactin, growth hormone, glucagon insulin and glucose were measured in non-treated control rats, bromocriptine-treated control rats and GH3-cell-tumor-bearing rats with and without bromocriptine treatment. Bromocriptine treatment increased plasma levels of glucagon, insulin and glucose in control rats. Tumor-bearing rats had increased body weight and increased plasma levels of prolactin, growth hormone, glucagon, insulin and glucose. Bromocriptine treatment reduced body weight and decreased the plasma levels of prolactin, glucagon and insulin, as compared to non-treated tumor-bearing rats. The drug had no effect on plasma levels of growth hormone and glucose. These results indicate that, in GH3-cell-tumor-bearing rats, prolactin, glucagon and insulin are more sensitive to the action of bromocriptine than growth hormone.
D000818:Animals; D001786:Blood Glucose; D001835:Body Weight; D001971:Bromocriptine / Q000494:pharmacology*; D002460:Cell Line; D005260:Female; D005934:Glucagon / Q000097:blood*; D013006:Growth Hormone / Q000378:metabolism*; D007328:Insulin / Q000097:blood*; D008297:Male; D009374:Neoplasms, Experimental / Q000097:blood*; D011388:Prolactin / Q000378:metabolism*; D051381:Rats; D011920:Rats, Inbred WF
D001786:Blood Glucose; D007328:Insulin; D001971:Bromocriptine; D011388:Prolactin; D013006:Growth Hormone; D005934:Glucagon